Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: Cardio Oncology Expert Panel Recommendations (JACC: CardioOncology State-of-the-Art Review December 2024)-Article: Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: Cardio Oncology Expert Panel Recommendations

Article: Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: Cardio Oncology Expert Panel Recommendations

Back to course

Pdf Summary

The expert panel report focuses on cardiovascular issues associated with cancer therapies. It highlights the development of cardiovascular toxicity (CTR-CVT) as a significant concern due to the wide range of cancer treatments, including chemotherapy, radiotherapy, immunotherapy, and targeted therapies. The report outlines four main strategies: cardioprotection, surveillance, permissive cardiotoxicity, and special considerations. <br /><br />1. Cardioprotection refers to strategies aiming to prevent cancer therapy-induced cardiovascular toxicity. It includes using angiotensin-converting enzyme inhibitors, beta-blockers, and statins to mitigate the risk of heart failure in patients undergoing anthracycline-based chemotherapy or other cardio-toxic therapies.<br /><br />2. Surveillance involves monitoring for signs of cardiovascular toxicity during cancer treatments, like echocardiography and biomarker tests. The aim is to identify toxicity early to intervene appropriately.<br /><br />3. Permissive cardiotoxicity allows cancer treatments to continue even if cardiotoxicity is present, provided the overall benefits outweigh the risks. This approach requires close monitoring and managing cardiovascular symptoms conservatively.<br /><br />4. Special considerations focus on invasive management of severe cardiovascular diseases in patients with advanced cancer, emphasizing the need for multidisciplinary approaches.<br /><br />The panel stresses the evidence gaps, calling for more research to advance understanding and improve patient care. It advocates for collaboration between oncologists and cardiologists to address these challenges effectively, emphasizing personalized strategies based on risk assessments and patient preferences.

Keywords

cardiovascular toxicity

cancer therapies

cardioprotection

surveillance

permissive cardiotoxicity

chemotherapy

radiotherapy

immunotherapy

multidisciplinary approaches

personalized strategies